BioMérieux: full acquisition of Lumed
The French in vitro diagnostics specialist is increasing its stake in this Canadian company, with which it has worked closely since 2017, from 16% to 100%, with the acquisition of 84% of the capital representing an investment of almost nine million euros.
According to bioMérieux, Lumed's solutions provide healthcare professionals with a variety of information they need to ensure better patient care, combat antibiotic resistance and improve infection control.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction